CDMO Samsung Biologics has entered into a series of manufacturing deals with a European pharmaceutical company.
The deals, which are worth more than USD $668m combined, will be fulfilled until December 2031.
Furthermore, the biologics-focused CDMO is planning to add antibody-drug conjugate (ADC) services to its portfolio.
To assist service expansion, the company is currently building a dedicated ADC development and production facility, which is scheduled to be completed by the end of this year.
At the site, Samsung Biologics will offer ADC process development and conjugation services.
President and CEO of Samsung Biologics, John Rim, commented: "We are delighted to expand our partnership with the European pharmaceutical company toward our shared commitment to delivering high-quality biopharmaceuticals to patients,"
"As we further expand strategic collaboration with clients worldwide, we also make continued investments in our capabilities and manufacturing technologies. Our goal is to provide the highest-quality services at every stage and deepen our trusted partnerships."
After this year, Samsung Biologics has partnered with 17 of the world's top 20 pharmaceutical companies.